Association of Gene Mutations with Response to Arsenic-Containing Compound Qinghuang Powder (复方青黄散) in Patients with Myelodysplastic Syndromes
- 4 Downloads
To investigate the relationship between gene mutations and response to Compound Qinghuang Powder (复方青黄散, CQHP) in patients with myelodysplastic syndrome (MDS).
Forty-three MDS patients were genotyped by ultra-deep targeted sequencing and the clinical data of patients were collected and the relationship between them was analyzed.
Up to 41.86% of patients harbored genet mutations, in most cases with more than one mutation. The most common mutations were in SF3B1, U2AF1, ASXL1, and DNMT3A. After treatment with CQHP, about 88.00% of patients no longer required blood transfusion, or needed half of prior transfusions.
CQHP is an effective treatment for patients with MDS, especially those with gene mutations in SF3B1, DNMT3A, U2AF1, and/or ASXL1.
Keywordsmyelodysplastic syndromes arsenic next-generation sequencing realgar
Unable to display preview. Download preview PDF.
- 7.Ma JL, Qu WW, Hu XM. Arsenic preparation for application in the treatment of myelodysplastic syndrome. Chin J Clin (Electr ed, Chin) 2012;6:149–150.Google Scholar
- 8.Hu XM, Wang HZ, Mao C, Liu C, Li L, Zheng CM, et al. Clinical significance of trisomy 8 and monosomy 7/7q deletion in myelodysplastic syndrome. J Clin Hematol (Chin) 2006;19:340–343.Google Scholar
- 9.Hu XM, Ma JL, Ma R. Selectivity of treatment to clone category in patients with myelodysplastic syndromes. J Leuk Lymph (Chin) 2011;20:759–761.Google Scholar
- 10.Ma JL, Qu WW, Hu XM. Correlationship of clonal selection of treatment with arsenious compound formula Qinghuang Powder with in vivo effects of arsenic in patients with myelodysplastic syndrome. Chin J Inf Tradit Chin Med (Chin) 2013;20:5–8.Google Scholar
- 11.Sun SZ, Ma R, Hu XM, Yang XH, Xu YG, Wang HG, et al. Karyotype and DNA-methylation responses in myelodysplastic syndromes following treatment with traditional Chinese formula containing arsenic. Evid Based Complement Alternat Med 2012;2012:969476.Google Scholar
- 13.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008:88–93.Google Scholar
- 14.Shaffer LG, Tommerup N, eds. An international system for human cytogenetic nomenclature. Basel: S. Karger Publishers; 2005.Google Scholar
- 15.Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, et al. International Working Group (IWG) consensus criteria for treatment response in myelofi brosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497–1503.CrossRefPubMedGoogle Scholar
- 16.Zheng XY, ed. Guidelines for the clinical research of traditional Chinese medicine (Trial). Beijing: China Medical Science and Technology Press; 2002:19–20.Google Scholar
- 17.Hu XM, Ma R, Xu YG, GUO XQ, Xu S, Liu F, et al. Application of Qinghuang Powder in treating hematologic malignancies. Int J Tradit Chin Med (Chin) 2011;33:568–570.Google Scholar
- 18.Xu S, Ma R, Hu XM. Clinical observation on Qinghuang Powder for treatment of 31 cases of myelodysplastic syndrome. J Tradit Chin Med (Chin) 2006;47:514–516.Google Scholar
- 19.Xu S, Hu XM, Xu YG, Yang XH, Wang HZ, Liu F, et al. Effect of treatment for myelodysplastic syndrome by Qinghuang Powder combined with Chinese herbs for reinforcing Shen and strenghening Pi. Chin J Integr Chin West Med (Chin) 2008;28:216–219.Google Scholar
- 20.Liu F, Guo XQ, Hu XM, Xu YG, Wang HZ, Yang XH, et al. Effect of Qinghuang Powder in treating 36 patients with myelodysplastic syndrome. J Tradit Chin Med (Chin) 2011;52:241–242.Google Scholar
- 22.Wang Y, Fang S, Song MM, Hu XM. Safety of compound Qinghuang powder in patients with myelodysplastic syndromes. Int J Tradit Chin Med (Chin) 2014;37:1074–1077.Google Scholar
- 23.Wang Y, Fang S, Deng ZY, Song MM, Ma JL, Yang XP, et al. Compound Qinghuang Powder in the treatment of patients with myelodysplastic syndromes. Int J Tradit Chin Med (Chin) 2015;37:1091–1095.Google Scholar
- 24.Wang FR, Lou YQ, Lu DP. Study on clinical pharmacokinetics of oral Tetraarsenic tetrasulfide. Chin J Hematol (Chin) 2005;26:44–46.Google Scholar
- 25.Ni JH, Chen GQ, Shen ZX, Li XS, Liu HW, Huang YT, et al. Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia. Chin J Hematol (Chin) 1997;18:250–253.Google Scholar
- 26.Hu XM, Tanaka S, Onda K, Yuan B, Toyoda H, Ma R, et al. Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7. Chin J Integr Med 2014;20: 387–393.CrossRefPubMedGoogle Scholar
- 28.Hu XM, Yuan B, Song MM, Onda K, Tanaka S, Toyoda H, et al. Dose-dependent biphasic effects of arsenic disulfi de on differentiation and apoptosis of HL-60 cells. Curr Topics Pharmacol (Chin) 2014;17:13–25.Google Scholar